CHMP March 2015: BI-Lilly closes in on diabetes fray
This article was originally published in Scrip
On 27 March 2015, the European Medicines Agency's advisors gave the BI-Lilly Diabetes Alliance a little push forward, voting in favor of Synjardy, its fixed dose combination (FDC) of SGLT2 inhibitor Jardiance (empagliflozin) with metformin for treating Type 2 diabetes mellitus. But while the decision in Europe is important, Europe is not a big market for FDC products in diabetes. BI-Lilly's real battle in the SGLT2 market will be fought around the long-term safety data of SGLT2 compounds and on their efficacy when combined in fixed doses with gliptins.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.